Chipotle, Starbucks, Palantir, Intel, SpaceX, Wolfspeed, and More Stocks That Explain Today’s Market
Chipotle trades higher following a report that Starbucks had looked into a possible takeover of the burrito chain. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
CSL Plasma plans to use Haemonetics’ plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement. Continue Reading
Haemonetics stock surges 17% on CSL Plasma supply deal update
Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc. Before you buy NVIDIA: our AI model's stock picks are beating the mar…
Stocks making the biggest moves premarket: Haemonetics, Broadcom, Lululemon, Wolfspeed & more
Check out the companies making the biggest moves premarket: Haemonetics — The blood and plasma provider popped 8% after CSL expects to complete the rollout of Haemonetics' plasmapheresis platform across the U.S. by the end of 2027. Wolfspe…
PAHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now? Let's tak…
3 Small-Cap Stocks with Questionable Fundamentals
3 Small-Cap Stocks with Questionable Fundamentals Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay…
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026. The Company will hold a…
Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the medical devices & suppl…
Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus
Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics' share price…
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) shares soared 5.2% in the last trading session to close at $6.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.5% ga…
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right no…
Haemonetics upgraded to Buy at BofA on supply deal with CSL
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Bank of America on Thursday upgraded Haemonetics (HAE [https://seekingalpha.com/symbol/HAE]) to Buy from Neutral, citing a recent supply deal the blood management solutions provider si…
Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls
Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
1 Momentum Stock with Competitive Advantages and 2 We Avoid
1 Momentum Stock with Competitive Advantages and 2 We Avoid Exciting developments are taking place for the stocks in this article. They've all surged ahead of the broader market over the last month as catalysts such as new products and pos…
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Orchestra BioMed Holdings, Inc. Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additiona…
GEHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors? We'll need to take a closer…
AZENTA ANNOUNCES LEADERSHIP TRANSITION
Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "th…
2 Momentum Stocks with Exciting Potential and 1 We Avoid
2 Momentum Stocks with Exciting Potential and 1 We Avoid Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market con…
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look…
1 Russell 2000 Stock with Competitive Advantages and 2 We Turn Down
1 Russell 2000 Stock with Competitive Advantages and 2 We Turn Down Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than thei…
Sector Update: Healthcare Stocks Climb Late Afternoon
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 1%.In corporate news, Haemonetic…
Haemonetics rises after supply deal with CSL
[Two coloured ropes knotted together] Richard Drury Shares of Haemonetics (HAE [https://seekingalpha.com/symbol/HAE]) added ~7% in the premarket on Tuesday after the blood management solutions provider disclosed a supply agreement with Aus…
1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid
1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will…
Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Haemonetics stock has delivered a strong 69.0% return over the past year, yet the valuation signa…
Haemonetics (HAE) Earnings Beat Puts Fair Value Back In Focus
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Haemonetics (HAE) has drawn fresh attention after reporting first quarter fiscal 2027 results, with…
5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call
5 Insightful Analyst Questions From Haemonetics's Q2 Earnings Call Haemonetics delivered a Q2 performance that surpassed Wall Street's revenue and adjusted earnings expectations, supported by consistent execution across its business lines.…
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics Corporation HAE posted first-quarter fiscal 2027 adjusted earnings of $1.14 per share, up 3.6% year over year. The figure beat the Zacks Consensus Estimate by 6.5%. On a GAAP basis, earnings per share were 72 cents compared wit…
Haemonetics (HAE) Q1 2027 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations and Treasurer - Olga GuyetteChief Executive Officer - Christopher SimonChief Financial Officer - James D'Arecca TA…
Haemonetics (HAE) Q1 2027 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations and Treasurer - Olga Guyette Chief Executive Officer - Christopher Simon Chief Financial Officer - James D'Arecca…
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
(RTTNews) - The following biotech stocks reached a 52-week high on August 12, 2026, driven up by key catalysts such as positive quarterly reports or promising results from clinical trials. BioVie Inc. (BIVI) BioVie is a clinical-stage biop…
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
Have you looked into how Haemonetics (HAE) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this provider blood management systems for health care providers and blood collectors,…
HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady
HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady Blood products company Haemonetics (NYSE:HAE) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 5.6% year on year to $339.4 mi…
Haemonetics Q1 Earnings Call Highlights
Key Points Interested in Haemonetics Corporation? Here are five stocks we like better. Haemonetics raised its fiscal 2027 outlook, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, after first-quarter revenue incr…
Haemonetics Corporation Q1 2027 Earnings Call Summary
Haemonetics Corporation Q1 2027 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap h…
Haemonetics Corp (HAE) (Q1 2027) Earnings Call Highlights: Strong Start Drives Raised Guidance
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Haemonetics Corp (NYSE:HAE) delivered a strong fir…
Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago. These figures are adjusted for non-recurring items. Thi…